<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3438">
  <stage>Registered</stage>
  <submitdate>17/01/2012</submitdate>
  <approvaldate>17/01/2012</approvaldate>
  <nctid>NCT01514487</nctid>
  <trial_identification>
    <studytitle>Comparison of Three Liraglutide Formulations in Healthy Volunteers</studytitle>
    <scientifictitle>A Randomised, Double-blind, Single-centre, Three-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Each of the Two New Liraglutide Formulations at pH 7.9 and 8.15 and the Planned Phase 3 Formulation at pH 7.7</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NN2211-1636</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes</healthcondition>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - liraglutide

Experimental: pH 7.7 - 

Experimental: pH 7.9 - 

Experimental: pH 8.15 - 


Treatment: drugs: liraglutide
One single dose of 0.75 mg administered on three different dosing occasions with a 14-day wash-out period between each dosing. Injected subtaneously

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Area under the Curve (0-t)</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Cmax, maximum concentration</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the curve (0-infinity)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>tmax, time to reach Cmax</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>tÂ½, terminal half-life</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Terminal elimination rate constant</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy subjects

          -  Good general health as judged by the investigator, based on medical history, physical
             examination including 12-lead ECG (electrocardiogram), vital signs and blood and
             urinary laboratory assessments.

          -  Body Mass Index (BMI) of 18-27 kg/m^2, both inclusive</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of any clinically significant renal, hepatic, cardiovascular, pulmonary,
             gastrointestinal,

          -  metabolic, endocrine, haematological, neurological, psychiatric disease or other major
             disorders

          -  that may interfere with the objectives of the study, as judged by the investigator

          -  Family or personal history of Primary hyperparathyroidism or pheochromocytoma or
             thyroid malignancy or multiple endocrine neoplasia

          -  Impaired renal function

          -  Uncontrolled treated/untreated hypertension

          -  Any clinically significant abnormal ECG

          -  Active hepatitis B and/or active hepatitis C

          -  Positive HIV (human immunideficiency virus) antibodies

          -  Known or suspected allergy to trial product(s) or related products

          -  Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate
             contraceptive measures

          -  Prescription or non-prescription medication, except for paracetamol and vitamins

          -  History of alcoholism or drug abuse during the last 12 months

          -  Smoking of more than 10 cigarettes per day, or the equivalent for other tobacco
             products

          -  Habitual excessive consumption of methylxanthine-containing beverages and foods
             (coffee, tea, soft drinks such as cola, chocolate) as judged by the Investigator</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>13/01/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>24</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>30/03/2005</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Novo Nordisk Investigational Site - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novo Nordisk A/S</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is conducted in Oceania. The aim of this trial is to test for bioequivalence
      between each of the two new liraglutide formulations at pH 7.9 and 8.15 and the planned Phase
      3 formulation at pH 7.7.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01514487</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Global Clinical Registry (GCR, 1452)</name>
      <address>Novo Nordisk A/S</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>